Innoviva Operating Income 2006-2020 | INVA

Innoviva operating income from 2006 to 2020. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Innoviva Annual Operating Income
(Millions of US $)
2019 $246
2018 $238
2017 $184
2016 $109
2015 $32
2014 $-34
2013 $-29
2012 $-25
2011 $-110
2010 $-78
2009 $-81
2008 $-93
2007 $-169
2006 $-179
2005 $-150
Innoviva Quarterly Operating Income
(Millions of US $)
2020-06-30 $76
2020-03-31 $76
2019-12-31 $74
2019-09-30 $61
2019-06-30 $60
2019-03-31 $52
2018-12-31 $77
2018-09-30 $58
2018-06-30 $63
2018-03-31 $41
2017-12-31 $66
2017-09-30 $40
2017-06-30 $48
2017-03-31 $29
2016-12-31 $38
2016-09-30 $28
2016-06-30 $26
2016-03-31 $18
2015-12-31 $17
2015-09-30 $8
2015-06-30 $5
2015-03-31 $1
2014-12-31 $0
2014-09-30 $-10
2014-06-30 $-10
2014-03-31 $-15
2013-12-31 $19
2013-09-30 $-8
2013-06-30 $-7
2013-03-31 $-33
2012-12-31 $-30
2012-09-30 $-33
2012-06-30 $-36
2012-03-31 $86
2011-12-31 $-36
2011-09-30 $-29
2011-06-30 $-24
2011-03-31 $-21
2010-12-31 $-18
2010-09-30 $-20
2010-06-30 $-19
2010-03-31 $-21
2009-12-31 $-21
2009-09-30 $-21
2009-06-30 $-21
2009-03-31 $-18
2008-12-31 $-15
2008-09-30 $-21
2008-06-30 $-27
2008-03-31 $-30
2007-12-31 $-34
2007-09-30 $-35
2007-06-30 $-48
2007-03-31 $-52
2006-12-31 $-41
2006-09-30 $-41
2006-06-30 $-45
2006-03-31 $-52
2005-12-31 $-44
2005-09-30 $-39
2005-06-30 $-33
2005-03-31 $-33
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.409B $0.261B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $394.028B 18.78
Roche Holding AG (RHHBY) Switzerland $297.019B 0.00
Pfizer (PFE) United States $212.995B 13.31
Merck (MRK) United States $209.118B 14.92
Novartis AG (NVS) Switzerland $194.379B 15.11
AbbVie (ABBV) United States $168.559B 10.27
Novo Nordisk (NVO) Denmark $157.984B 25.70
AstraZeneca (AZN) United Kingdom $148.907B 28.95
Eli Lilly (LLY) United States $145.910B 22.27
Sanofi (SNY) $129.689B 15.41
GlaxoSmithKline (GSK) United Kingdom $105.759B 13.87
Bayer (BAYRY) Germany $63.563B 9.16
H Lundbeck (HLUYY) Denmark $7.482B 13.00